Pharma BD Deal Intelligence
Exact Sciences acquired Genomic Health for $2.8 billion, uniting Oncotype DX breast, prostate, and colon recurrence-score tests under one genomic diagnostics platform backed by international commercial infrastructure in 90+ countries. The combined portfolio, anchored by TAILORx trial data, positioned Exact Sciences as a leader in precision oncology testing.
Restore: 'for up to $100M'; 'Abbott agreed to acquire Exact Sciences for $105/share (~$21B equity, ~$23B enterprise value)' (per MDxHealth and Abbott sources on the record).
Exact Sciences completed $2.8B acquisition of Genomic Health, combining Cologuard colorectal screening with Oncotype DX cancer genomic tests.
Combined entity became largest precision oncology diagnostics company with Oncotype DX as standard-of-care in early breast cancer treatment decisions.
Exact Sciences sold the Oncotype DX Genomic Prostate Score business (via Genomic Health) to MDxHealth for up to $100M; GPS revenue ceased after transition in Q3 2024.
Exact Sciences reported over $2.5B combined revenue driven by Cologuard growth and steady Oncotype DX adoption globally.
Abbott agreed to acquire Exact Sciences for $105/share (~$21B equity, ~$23B EV); expected close Q2 2026.
Created precision diagnostics powerhouse at $2.5B+ revenue. Oncotype DX complemented Cologuard strategically. Multi-cancer detection leadership achieved.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Exact Sciences Corporation / Genomic Health, Inc. (this deal) | 2019 | $2.8B | 81 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2019 deals · Oncology deals